SCHEMBL5350074

SCHEMBL5350074

NC(=O)c1ccc(Cl)cc1Oc1cccc(CNC(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.51
PPARD Q03181 8/20 0.51
PPARA Q07869 8/20 0.51
ANO1 Q5XXA6 1/20 0.47
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AKR1B1 P15121 1/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.43
RPS6KB1 P23443 1/20 0.43
CD38 P28907 1/20 0.42
CTNNB1 P35222 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175963 0.86 ANO1 (0.48) PPARGPPARDPPARAANO1ALDH1A1
SCHEMBL5349683 0.81 MAPK14 (0.47) PPARGPPARDPPARAANO1ALDH1A1
SCHEMBL6178811 0.80 HPGD (0.51) PPARGPPARDPPARAANO1ALDH1A1
SCHEMBL27623179 0.79 CTNNB1 (0.65) ALDH1A1GAAHPGDHTTATM
SCHEMBL7834257 0.79 MRGPRX4 (0.50) PPARGPPARDPPARAANO1ALDH1A1
SCHEMBL5206113 0.78 ADAMTS5 (0.48) PPARGPPARDPPARAANO1ALDH1A1
Hydrochloric Acid SCHEMBL5346287 0.76 PLAU (0.49) PPARGPPARAPTGDR2
SCHEMBL3552958 0.73 RXFP1 (0.59) ALDH1A1HPGDHTTL3MBTL1CYP1A2
SCHEMBL6176779 0.73 PPARG (0.46) PPARGPPARDPPARAANO1ALDH1A1
SCHEMBL6175341 0.72 ALDH1A1 (0.44) PPARGPPARDPPARAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276528-B2 Compounds for the inhibition of nitric oxide synthase ASTRAZENECA AB (SE) 2007-10-02 US disclosed
US-7119122-B2 Compounds for the inhibition of nitric oxide synthase ASTRAZENECA AB (SE) 2006-10-10 US disclosed
US-20060217424-A1 Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain CONNOLLY STEPHEN 2006-09-28 US disclosed
US-20040260088-A1 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines ASTRAZENECA AB (SE) 2004-12-23 US disclosed
EP-1434756-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-07-07 EP disclosed
WO-2003029185-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040260088-A1 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines NOS1, NOS3, NOS2 PPARG 2807/4885PPARD 3817/4885PPARA 4035/4885
US-20060217424-A1 Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain NOS3, NOS1, NOS2 PPARG 934/4885PPARD 1984/4885PPARA 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.